Phase 2 Relapsed/Refractory Clinical Trials
38 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 38 trials
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 1Phase 2
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals220 enrolled19 locationsNCT06292780
Recruiting
Phase 1Phase 2
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Amgen104 enrolled4 locationsNCT07134088
Recruiting
Phase 1Phase 2
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Relapsed/RefractoryB-cell Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center40 enrolled1 locationNCT06287229
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled83 locationsNCT04973605
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 1Phase 2
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals186 enrolled7 locationsNCT06669247
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 2
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
Chinese PLA General Hospital200 enrolled1 locationNCT06084819
Recruiting
Phase 2
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia (PCL)
The First Hospital of Jilin University25 enrolled1 locationNCT07509086
Recruiting
Phase 1Phase 2
Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
Relapsed/Refractory B-cell Lymphoma
Shenzhen University General Hospital20 enrolled1 locationNCT07508605
Recruiting
Phase 2Phase 3
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 2
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Relapsed/Refractory Peripheral T Cell Lymphoma
Fudan University25 enrolled1 locationNCT06519526
Recruiting
Phase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple MyelomaRelapsed/Refractory Multiple Myeloma
C4 Therapeutics, Inc.100 enrolled3 locationsNCT07284758
Recruiting
Phase 1Phase 2
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb240 enrolled11 locationsNCT07325136
Recruiting
Phase 2
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University33 enrolled1 locationNCT07418190
Recruiting
Phase 2
The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
Relapsed/Refractory Immune Thrombocytopenia
Seoul National University Hospital29 enrolled4 locationsNCT05599880
Recruiting
Phase 1Phase 2
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Haihe Biopharma Co., Ltd.100 enrolled1 locationNCT06909877
Recruiting
Phase 2
Phase II Clinical Trial of Drug Combinations Guided by Ex-vivo Testing in Patients With Relapsed/Refractory T-cell Lymphoma (COMBINEX-T)
Relapsed/Refractory Peripheral T-cell Lymphoma (RR PTCL)
National University Hospital Singapore36 enrolled1 locationACTRN12626000088347